Lefamulin or moxifloxacin for community-acquired pneumonia: balancing innovation, safety, and evidence
Open Access
- 22 November 2025
- journal article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 1001-1002
Abstract
The recent approval of lefamulin presents an alternative to fluoroquinolones for community-acquired pneumonia. In recent trials, lefamulin matched moxifloxacin in early clinical response and safety, with a favorable activity spectrum including atypical pathogens. However, fluoroquinolones remain entrenched due to cost, clinician familiarity, and broad guidelines. This letter examines current evidence comparing the two, highlights potential niches for lefamulin, and calls for more trials to guide adoption in diverse healthcare settings.Keywords
This publication has 6 references indexed in Scilit:
- Efficacy of Lefamulin for Community-Acquired Bacterial Pneumonia (CABP) Patients: Pooled Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 1, LEAP 2 and LEAP China TrialsInfection and Drug Resistance, 2025
- Lefamulin Rivals Moxifloxacin in Treating Community-Acquired Bacterial Pneumonia: Evidence from a Randomized TrialBulletin of Pharmaceutical Sciences Assiut University, 2025
- In vitro Activity of Lefamulin Against the Common Respiratory Pathogens Isolated From Mainland China During 2017–2019Frontiers in Microbiology, 2020
- Lefamulin (Xenleta) for the Treatment of Community -Acquired Bacterial Pneumonia2020
- LefamulinHospital Pharmacy, 2020
- Risks associated with the therapeutic use of fluoroquinolonesExpert Opinion on Drug Safety, 2013